Somewhat Positive News Coverage Somewhat Unlikely to Affect Galmed Pharmaceuticals (GLMD) Share Price

News articles about Galmed Pharmaceuticals (NASDAQ:GLMD) have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Galmed Pharmaceuticals earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.0277981030559 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Galmed Pharmaceuticals (NASDAQ:GLMD) opened at $11.07 on Friday. Galmed Pharmaceuticals has a 12 month low of $3.85 and a 12 month high of $12.22. The stock has a market cap of $167.04, a PE ratio of -9.07 and a beta of 2.46.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Wednesday. Maxim Group set a $14.00 price objective on shares of Galmed Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Seaport Global Securities reiterated a “buy” rating and set a $19.00 price target on shares of Galmed Pharmaceuticals in a report on Friday, October 6th. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Galmed Pharmaceuticals in a report on Friday, October 27th. Finally, ValuEngine lowered shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Galmed Pharmaceuticals has an average rating of “Buy” and a consensus price target of $19.20.

TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Galmed Pharmaceuticals (GLMD) Share Price” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2018/01/14/galmed-pharmaceuticals-glmd-receives-news-sentiment-score-of-0-16-updated-updated.html.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Insider Buying and Selling by Quarter for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply